USPTO Examiner LIPPERT JOHN WILLIAM - Art Unit 1615

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19077685MANUFACTURING OF BUPIVACAINE MULTIVESICULAR LIPOSOMESMarch 2025May 2025Allow200YesNo
18977838LEONURINE NANOCOMPOSITE HYDROGEL AND PREPARATION METHODS AND APPLICATIONS THEREOFDecember 2024April 2025Allow410NoNo
18761898MANUFACTURING OF BUPIVACAINE MULTIVESICULAR LIPOSOMESJuly 2024January 2025Allow710YesNo
18762128MANUFACTURING OF BUPIVACAINE MULTIVESICULAR LIPOSOMESJuly 2024February 2025Allow710YesNo
18565894CATIONIC LIPID COMPOUND, COMPOSITION CONTAINING SAME AND USE THEREOFNovember 2023September 2024Allow1010NoNo
18546845USE OF CATIONIC PORPHYRINS AS SELECTIVE HERBICIDEAugust 2023December 2025Allow2810YesNo
18357485Compounds, Pharmaceuticals, Formulations, and Methods for Treating and Preventing RNA Virus Infections and Associated DiseasesJuly 2023March 2026Abandon3110NoNo
18255498HYDRATING COMPOSITION COMPRISING POLYMERS AND A COMPOUND CHOSEN FROM MENTHOL AND ITS DERIVATIVESJune 2023February 2026Abandon3210NoNo
18202981LIPOSOMIC DRUG-DELIVERY VEHICLESMay 2023February 2026Allow3210NoNo
18038871PEPTIDE HAVING PROTECTIVE ACTIVITY AGAINST CELL DAMAGE CAUSED BY PARTICULATE MATTER, AND USES FOR SAMEMay 2023July 2025Allow2500YesNo
18321613PREPARATION METHOD AND APPLICATION OF TUMOR MICROPARTICLES ENCAPSULATING METABOLIC INHIBITORSMay 2023June 2025Allow2500YesNo
18247976IMPROVED PROCESS AND FORMULATION OF LIPID NANOPARTICLESApril 2023March 2026Allow3520NoNo
18028614COMBINATIONS OF TRIAZINONE HERBICIDES WITH SAFENERSMarch 2023March 2026Abandon3520NoNo
18028617LIPID COMPOSITIONS COMPRISING POLYNUCLEOTIDE ANTIGENSMarch 2023January 2026Abandon3310NoNo
17909486METHOD FOR PREPARING A FORMULATION FOR INDUCING AN IMMUNE RESPONSE OF A PLANT TO A PATHOGEN, AND FORMULATIONMarch 2023August 2025Allow3500YesNo
18112720REDUCING HYDROPHOBIC DRUG ADSORPTION IN ECMO CIRCUITSFebruary 2023December 2025Abandon3310NoNo
18021705METHOD OF MODULATING SENSITIVITY TO TYROSINE KINASE INHIBITORFebruary 2023January 2026Allow3510NoNo
18019685PLANT PATHOGEN DEFENCE ELICITORSFebruary 2023January 2026Allow3500YesNo
18160263Encapsulation of cannabinoidsJanuary 2023September 2025Abandon3241NoNo
18016865RAPAMYCIN (RAPA) FORMULATION AND PREPARATION METHOD THEREOFJanuary 2023November 2025Abandon3410NoNo
18156534SKIN WHITENING COMPOSITIONJanuary 2023April 2024Abandon1510NoNo
18081752COSMETIC COMPOSITION COMPRISING POLYACRYLATE CROSSPOLYMER-6, AND SILICA AND/OR LAUROYL LYSINEDecember 2022February 2025Abandon2630NoNo
17994217SUSTAINED-RELEASE PHEROMONE PREPARATIONNovember 2022June 2025Allow3030YesNo
17999916NOVEL METHACRYLATE COPOLYMER AND COMPOSITIONS COMPRISING ITNovember 2022July 2025Allow3110YesNo
17997850BEAUTY MICRONEEDLE ARRAYNovember 2022November 2025Abandon3610NoNo
17979303COSMETIC PRODUCT COMPRISING OIL DISCONTINUOUS PHASE AND METHOD OF USE THEREOFNovember 2022May 2024Abandon1810NoNo
17978667PRODUCTION PROCESS OF A CONVENIENT AND QUICK-ADHESIVE EYELASHESNovember 2022April 2024Abandon1710NoNo
18049535POLYMERIC DELIVERY SYSTEMSOctober 2022October 2025Allow4531YesNo
17920582Nanotherapy Targeting RHAMM-Positive TumorsOctober 2022January 2026Allow3910YesNo
17970649SKIN HEALTH PRESERVATION TREATMENT FORMULATIONOctober 2022October 2024Abandon2321NoNo
17919415INJECTABLE OIL-BASED PHARMACEUTICAL COMPOSITIONOctober 2022October 2025Abandon3620NoNo
179959192-DEOXY-D-GLUCOSE FOR PREVENTION AND TREATMENT OF A VIRAL DISEASE, IN PARTICULAR OF COVID-19October 2022October 2025Abandon3610NoNo
17957707ACIDIC BONDING COMPOSITIONS AND METHODS FOR RESTORING AND COLOR TONING LIGHTENED HAIRSeptember 2022January 2025Allow2731YesYes
17995254REMDESIVIR AND REMDESIVIR ANALOGS, SOLUTIONS, AND NANOPARTICLE, LIPOSOMAL, AND MICROPARTICLE COMPOSITIONS FOR TREATING VIRAL INFECTIONSSeptember 2022September 2025Allow3610NoNo
17956528PHARMACEUTICAL FORMULATION CONTAINING A PSYCHEDELIC SUBSTANCE OBTAINED BY SELECTIVE LASER SINTERING (SLS) 3D PRINTINGSeptember 2022August 2024Abandon2310NoNo
17911327THERAPEUTIC SYSTEM FOR THE TOPICAL, TRANSDERMAL AND TRANSCUTANEOUS APPLICATION OF CARBON MONOXIDESeptember 2022January 2026Allow4020YesNo
17905949Solid Deep Eutectic Solvent Formulation PlatformSeptember 2022August 2025Abandon3510NoNo
17939690Crosslinking Submucosal Injectate SystemSeptember 2022August 2025Allow3510YesNo
17909199MICROEMULSION-BASED VACCINE DELIVERY SYSTEM, PREPARATION METHOD THEREFOR AND USE THEREOFSeptember 2022December 2025Allow3920NoNo
17884997Lipid Composition and Use Thereof for Delivery of a Therapeutically Active Agent to EndotheliumAugust 2022August 2025Abandon3610NoNo
17796599COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATMENT OF MASTITISJuly 2022January 2026Allow4120YesNo
17812746HEMOSTATIC NANOCAPSULES FOR STOPPING BLEEDING, VISUALIZING INJURY, AND DELIVERING DRUGSJuly 2022August 2024Allow2511NoNo
17864485MICROBEADS FOR EMBOLIZATION AND COMPOSITION FOR TREATING PROLIFERATIVE DISEASESJuly 2022February 2026Abandon4320NoNo
17787156KIT FOR PREPARING NANOPARTICLE COMPOSITION FOR DRUG DELIVERY, COMPRISING POLYLACTIC ACID SALTJune 2022October 2025Allow4020NoNo
17843703FULLERENE GALLIUM PHOSPHONATE AND METHODSJune 2022June 2025Abandon3610NoNo
17755758USE OF OCTENYL-SUCCINATE STARCHES AS A BINDER IN WET GRANULATIONMay 2022September 2025Allow4020YesNo
17737982LIGHT STABLE SILVER CONTAINING NEAR NEUTRAL pH DISINFECTANT AND METHOD OF PREPARATIONMay 2022August 2024Allow2710NoNo
17774575NANO COMPLEX FOR TARGETED REPAIRING OF NEUROVASCULAR LESION, AND PREPARATION AND USE THEREOFMay 2022May 2025Allow3710YesNo
17771856STABILIZED AMORPHOUS CALCIUM MAGNESIUM PHOSPHATE PARTICLE COMPOSITIONSApril 2022April 2025Allow3501NoNo
17768621Microsphere-Drug CombinationApril 2022September 2025Allow4120NoNo
17768543PERSONAL CARE FORMULATIONApril 2022April 2025Allow3610NoNo
17766722MEMBRANE-BASED TWO COMPONENT THERAPEUTIC GAS RELEASE SYSTEM FOR ORAL ADMINISTRATIONApril 2022November 2025Allow4310NoNo
17765893THREE-DIMENSIONAL FLOW PATH STRUCTURE BODY AND NANOPARTICLE PRODUCTION METHOD USING SAMEApril 2022May 2025Abandon3710NoNo
17764432ANTI-UV COSMETIC COMPOSITIONMarch 2022May 2025Abandon3710NoNo
17803220Formulated and/or co-formulated compositions containing A2aR antagonist prodrugs useful in the treatment of cancer and methods thereofMarch 2022January 2026Allow4620NoNo
17761019ROPINIROLE-CONTAINING PATCH AND METHOD FOR IMPROVNG SKIN PERMEABILITY OF ROPINIROLEMarch 2022January 2026Abandon4630YesNo
17640749EXTRACELLULAR VESICLE-FENRETINIDE COMPOSITIONS, EXTRACELLULAR VESICLE-C-KIT INHIBITOR COMPOSITIONS, METHODS OF MAKING AND USES THEREOFMarch 2022March 2025Abandon3710NoNo
17632669POLYMER COATING AGENT HAVING CONCURRENTLY EXCELLENT WATER AND OIL REPELLENT PROPERTIES AND COSMETIC COMPOSITION COMPRISING SAME SHOWING EXCELLENT MAKE-UP PERSISTENCYFebruary 2022August 2025Allow4220YesNo
17632262LIPID NANOPARTICLE COMPOSITIONS COMPRISING CLOSED-ENDED DNA AND CLEAVABLE LIPIDS AND METHODS OF USE THEREOFFebruary 2022February 2026Abandon4921NoNo
17630861NANOMATERIALS CONTAINING CONSTRAINED LIPIDS AND USES THEREOFJanuary 2022November 2025Allow4520YesNo
17625659COSMETIC COMPOSITION CONTAINING GRAPHENE QUANTUM DOTS AS ACTIVE INGREDIENTJanuary 2022August 2025Allow4430NoNo
17597280BIOCOMPATIBLE COMPOSITIONS COMPRISING A BIOCOMPATIBLE THICKENING POLYMER AND A CHITOSAN DERIVATIVEDecember 2021August 2025Allow4320YesNo
17597232ISOXAZOLINE COMPOUNDS AND USE THEREOFDecember 2021April 2025Allow3910NoNo
17616346METHYLOBACTERIUM SP. NOV. STRAIN, COMPOSITIONS COMPRISING IT, AND ITS USE AS BIOSTIMULANT AND ENDOPHYTE NITROGEN-FIXING BACTERIUMDecember 2021July 2025Allow4420YesNo
17615967OIL-IN-WATER TYPE EMULSION LIP COSMETICDecember 2021June 2025Abandon4320NoNo
17595176DRY MICROPARTICLESNovember 2021December 2025Abandon4920NoNo
17595156LIPID NANOPARTICLENovember 2021May 2025Allow4320YesNo
17609958MICROPARTICLES COMPRISING CELLULOSE NANOCRYSTALS AGGREGATED WITH PROTEINS AND COSMETIC USES THEREOFNovember 2021December 2024Abandon3710NoNo
17437290EYE DROPS CONTAINING CHITOSAN NANOPARTICLES IN WHICH PDRN IS ENCAPSULATED, AND PREPARATION METHOD THEREFORNovember 2021May 2025Allow4520NoNo
17606718PRODUCTS OF MANUFACTURE AND METHODS FOR TRANSDERMAL DELIVERY OF PHARMACEUTICALS, ELECTROLYTES, AND NUTRICEUTICALSOctober 2021January 2025Abandon3810NoNo
17605367LIPOSOMAL SUSTAINED-RELEASE COMPOSITIONS CONTAINING A THERAPEUTIC DRUG AND USE THEREOFOctober 2021September 2025Allow4730NoNo
17603339USE OF GOLD NANOCLUSTERS IN TREATING HYPERCHOLESTEROLEMIA OR HYPERCHOLESTEROLEMIA-ASSOCIATED DISEASESOctober 2021May 2025Abandon4320NoNo
17601144ANTISEPTIC SKIN PREP COMPOSITIONOctober 2021April 2025Allow4220NoNo
17600965SOLID NANOPARTICLE FORMULATION OF WATER INSOLUBLE PHARMACEUTICAL SUBSTANCES WITH REDUCED OSTWALD RIPENING AND IMMEDIATE DRUG RELEASE FOLLOWING INTRAVENOUS ADMINISTRATIONOctober 2021November 2024Abandon3810NoNo
17599753FROZEN, POROUS THIN FILMS AND METHODS OF MAKING AND USE THEREOFSeptember 2021October 2025Allow4930YesNo
17593981PERSONAL CARE COMPOSITIONS AND METHODS COMPRISING TRANS-1-CHLORO-3,3,3-TRIFLUOROPROPENE AND TRANS-1,3,3,3-TETRAFLUOROPROPENESeptember 2021April 2025Abandon4320NoNo
17598956COSMETIC COMPOSITIONSeptember 2021June 2025Allow4420YesNo
17599369POSS VISCOELASTIC HEMOSTATIC AGENTSSeptember 2021February 2026Allow5240NoNo
17598515DRUG DELIVERY COMPOSITIONSeptember 2021February 2026Allow5331YesNo
17442949Method of Making Prodrug for Sustained and Controlled ReleaseSeptember 2021November 2024Allow3710NoNo
17442746Doxorubicin Containing Nanoplexes and Uses ThereofSeptember 2021April 2025Allow4211NoNo
17441844BENZOXAZINE MONOMERS AND POLYMERIC COATINGSSeptember 2021October 2025Abandon4921YesNo
17439911NANOPARTICLE, METHOD FOR PRODUCING NANOPARTICLE, AND PHARMACEUTICAL COMPOSITIONSeptember 2021November 2024Abandon3810NoNo
17438892TRANSPARENT OR SEMITRANSPARENT INVERSE MICROLATICES OF POLYACRYLAMIDE AS OIL EMULSION DRIFT REDUCING AGENTSeptember 2021May 2025Allow4420NoNo
17437442Supraparticle FormulationsSeptember 2021October 2025Allow5030NoNo
17435150HIGHLY STRUCTURED POROUS SILICA MATERIALS AND BIOLOGICAL USES THEREOFAugust 2021August 2025Allow4721NoNo
17433470MATERIAL AND SYSTEM FOR THE THERAPEUTIC TREATMENT OF JOINTSAugust 2021October 2025Abandon5040NoNo
17401654CIPROFLOXACIN POLYMORPH AND ITS USEAugust 2021October 2024Abandon3810NoNo
17430497BIOBASED PEARLESCENT WAXESAugust 2021April 2025Allow4421NoNo
17400376Late-Stage Product Differentiation Process for Personal Care ProductsAugust 2021June 2024Allow3410YesNo
17430132LONG-ACTING PHOTORECEPTOR-BINDING NANOPARTICLES, AND COMPOSITIONS AND METHODS THEREOFAugust 2021September 2025Allow4930NoNo
17428256WOUND CONTACT LAYER AND DRESSING FOR IODINE DELIVERYAugust 2021March 2026Allow5550YesNo
17310351PARTICLES OF A MIXTURE OF IRON(III)-OXYHYDROXIDE, SUCROSE AND ONE OR MORE STARCHES, PREFERABLY OF SUCROFERRIC OXYHYDROXIDEJuly 2021March 2025Allow4311NoNo
17424780METHODS OF PREPARING LIPID NANOPARTICLESJuly 2021January 2026Allow5441YesNo
17423862Production and Use of Yeast Extract as a Medical AdjuvantJuly 2021April 2025Abandon4520NoNo
17423380CHITOSAN-BASED NANOCOMPOSITE AS AN ANTIMICROBIAL AGENT AND CORROSION INHIBITORJuly 2021October 2025Allow5141NoNo
17251521POLYION COMPLEX MICELLE THAT INCLUDES ANTISENSE OLIGONUCLEOTIDE AND BLOCK COPOLYMER OF PEG BLOCK AND CATIONIC POLYMER, SAID BLOCK COPOLYMER HAVING NUMBER-AVERAGE MOLECULAR WEIGHT OF 3-10 kDaJuly 2021September 2024Abandon4510NoNo
17418616GEL-TYPE COSMETICJune 2021November 2025Allow5240YesNo
17417160OIL-IN-WATER TYPE PEST REPELLENT COMPOSITIONJune 2021June 2024Abandon3610NoNo
17417263METHOD FOR CONTROLLING WEEDJune 2021August 2024Abandon3810NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner LIPPERT, JOHN WILLIAM.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
1
Examiner Affirmed
0
(0.0%)
Examiner Reversed
1
(100.0%)
Reversal Percentile
91.1%
Higher than average

What This Means

With a 100.0% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.

Strategic Value of Filing an Appeal

Total Appeal Filings
1
Allowed After Appeal Filing
1
(100.0%)
Not Allowed After Appeal Filing
0
(0.0%)
Filing Benefit Percentile
95.6%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 100.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Examiner LIPPERT, JOHN WILLIAM - Prosecution Strategy Guide

Executive Summary

Examiner LIPPERT, JOHN WILLIAM works in Art Unit 1615 and has examined 73 patent applications in our dataset. With an allowance rate of 56.2%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 44 months.

Allowance Patterns

Examiner LIPPERT, JOHN WILLIAM's allowance rate of 56.2% places them in the 17% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by LIPPERT, JOHN WILLIAM receive 2.19 office actions before reaching final disposition. This places the examiner in the 60% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by LIPPERT, JOHN WILLIAM is 44 months. This places the examiner in the 14% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +36.1% benefit to allowance rate for applications examined by LIPPERT, JOHN WILLIAM. This interview benefit is in the 84% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 32.9% of applications are subsequently allowed. This success rate is in the 70% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 28.6% of cases where such amendments are filed. This entry rate is in the 40% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 50.0% of appeals filed. This is in the 14% percentile among all examiners. Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.

Petition Practice

When applicants file petitions regarding this examiner's actions, 0.0% are granted (fully or in part). This grant rate is in the 0% percentile among all examiners. Strategic Note: Petitions are rarely granted regarding this examiner's actions compared to other examiners. Ensure you have a strong procedural basis before filing a petition, as the Technology Center Director typically upholds this examiner's decisions.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 0% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 4.9% of allowed cases (in the 80% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.